Click HERE to sign up for our newsletter to receive FREE stock updates delivered to right your email address!!

"The only thing necessary for the triumph of evil is for good men to do nothing."
- Edmund Burke

"What we call the secret of happiness is no more a secret than our willingness to choose life."
- Leo Buscaglia

"Do not follow where the path may lead. Go instead where there is no path and leave a trail."
- Harold R. McAlindon

"The history of the world is but the biography of great men."
- Thomas Carlyle

"Go to the people. Learn from them. Live with them. Start with what they know. Build with what they have. The best of leaders, when the job is done, when the task is accomplished, the people will say we have done it ourselves."
- Lao Tzu

"Leadership: The art of getting someone else to do something you want done because he wants to do it."
- Dwight D. Eisenhower

"Action expresses priorities."
- Mahatma Gandhi

"Try not to become a man of success but a man of value."
- Albert Einstein

"To climb steep hills requires a slow pace at first."
- Shakespeare

"There are three ingredients in the good life: learning, earning, and yearning."
- Christopher Morely

"The secret of success in life is for a man to be ready for his opportunity when it comes."
- Earl of Beaconsfield

"Success does not consist in never making blunders, but in never making the same one a second time."
- Josh Billings

"A penny saved is a penny earned."
- Benjamin Franklin

Welcome to Penny Performers

There are no other types of stocks like Penny Stocks. Penny Stocks are by far the most risky and potentially the most profitable investment that you can make. Our goal is to bring you Penny Stocks that Perform. There is huge risk involved and potentially even bigger returns. And as you will read below...

The Returns Are What It's All About!!!


Click on the name of a featured company for additional information. 

FEATURED STOCKS

Xynergy Holdings, Inc. is strategically placed to become take advantage of the growing presence of a global energy imperative. The company understands meeting the world’s energy challenges requires an integrated set of solutions. 

This understanding has led to the development of several approaches that define Xynergy’s commitment to meeting the world’s growing energy needs, while also promoting environmentally conscious business practices and sustainability, by promoting global commerce within the realm of a global economy.  

Xynergy also recognizes the key role fossil fuels will continue to play in the worlds energy mix.  This understanding enables them to focus, commit and contribute to global energy security through a diverse approach toward the development of both new and existing technologies that will increase energy efficiency, while at the same time promote sustainable and renewable energy sources.

They have diversified from a simple R&D company to a more revenue-driven, acquisition-minded organization.  The management team has identified several acquisition candidates internationally that will build shareholder equity, company assets, and open up doors of commerce through these potential acquisitions. 

Compugen’s mission is to be the world leader in the discovery and licensing of product candidates to the drug and diagnostic industries under milestone and revenue sharing agreements. The Company’s increasing inventory of powerful and proprietary discovery platforms is enabling the predictive discovery – field after field – of numerous therapeutic and diagnostic product candidates.

These discovery platforms are based on the Company’s decade-long focus on the predictive understanding of important biological phenomena at the molecular level. Compugen’s current collaborations include Biosite, Medarex, Inc., Merck & Co., Inc., Ortho-Clinical Diagnostics (a Johnson & Johnson company), Roche, Siemens Healthcare Diagnostics, Inc., and Teva Pharmaceutical Industries. In 2002, Compugen established an affiliate – Evogene Ltd. (TASE:
EVGN.TA) – to utilize the Company’s in silico predictive discovery capabilities in the agricultural biotechnology field.
eWorld Companies, Inc. is an online marketing & advertising technologies company that develops and markets cutting edge technologies using rich media, flash, animation and 3D graphics to help individuals and businesses market and advertise on the Internet. eWorld Companies, Inc. markets and distributes these technologies through its wholly-owned subsidiary eWorld Entertainment, Inc. (eWorlde) and its International network of Affiliates, users and strategic partners.

eWorld's unique and patented Boomerang Media Station®, named for its ability to return to the user's screen no matter what web site you visit, is a free software program that streams rich media within the actual application and remains ever-present as the user browses the Internet, offering the user one-click access to limitless entertainment experiences and convenience benefits. eWorld's WALRUS“ system which is downloaded along with Boomerang, continues to work in the background to provide assistance as the user searches, surfs or shops the Net, suggesting relevant topics, products and services based on each user's browsing and searching habits.
SpongeTech(R) Delivery Systems is a development stage company, which designs, produces, and markets a unique line of reusable cleaning products for household use. These sponge-based products utilize SpongeTech(R)'s(R) proprietary, patent (and patent-pending) technologies involving hydrophilic (liquid absorbing) foam and polyurethane matrices. The Company's sponges are specially configured with an outer contact layer and an inner matrix, the latter of which comes pre-loaded with specially formulated soaps and wax that are released when the sponge is wetted and applied to a surface with minimal pressure. The Company's current product line is designed for Car Care and Pet Care, however, SpongeTech(R) is currently exploring additional applications for its technology including an anti-bacterial, kitchen and bath cleaner, as well as a unique 'foaming' bath sponge for children.
ERHC Energy Inc. is a Houston-based independent oil and gas company focused on growth through high impact exploration in the highly prospective Gulf of Guinea and the development of undeveloped and marginal oil and gas fields. ERHC is committed to creating and delivering significant value for its shareholders, investors and employees, and to sustainable and profitable growth through risk balanced smart exploration, cost efficient development and high margin production.


Their strategy is to build a broad therapeutic portfolio through a combination of internal development and acquisition/in-licensing activities and to utilize their specialty sales force to promote their products in neurology and psychiatry. They apply novel formulation and delivery technologies to well-proven drug molecules and new chemical entities with known mechanisms of action to enhance patient care by improving efficacy, reducing adverse side effects or increasing patient compliance relative to existing therapies.

Their mission is to improve patients’ lives by identifying, developing and commercializing valuable pharmaceutical products in focused therapeutic areas. They address serious conditions in neurology and psychiatry that are poorly understood – all with the goal of improving patient care. Keeping patients firmly in mind inspires them to bring innovative and valuable resources to those in need.
Kratos Defense & Security Solutions, Inc. (Nasdaq:KTOS) provides mission critical engineering, IT services and war fighter solutions for the U.S. federal government and for state and local agencies. Principal services include C4ISR, weapon systems sustainment, military weapon range operations and technical services, network engineering services, information assurance and cybersecurity solutions, security and surveillance systems, and critical infrastructure design and integration. The Company is headquartered in San Diego, California, with resources located throughout the U.S. and at key strategic military locations.
Universal Detection Technology (OTCBB: UNDT) has licensed a spore detection technology from NASA's Jet Propulsion Laboratory (JPL) and has developed a first of its kind real-time continuous detection device capable of identifying abnormal levels of bacterial spores in the air, an indication of a possible anthrax attack. The Company constantly seeks to license new technologies based on which it can transform cutting edge science into tangible and everyday products.

Additionally, the Company offers its expert advice to customers with regards to a variety of subjects including post and pre incident planning, bio-terror detection for large events, and drafting customized security plans for customers interested in taking a proactive approach against bio-terrorism.

RF Micro Devices, Inc. (RFMD®) is a global leader in the design and manufacture of high-performance semiconductor components. RFMD's products enable worldwide mobility, provide enhanced connectivity and support advanced functionality in the cellular handset, wireless infrastructure, wireless local area network (WLAN), CATV/broadband and aerospace and defense markets. RFMD is recognized for its diverse portfolio of semiconductor technologies and RF systems expertise and is a preferred supplier to the world's leading mobile device, customer premises and communications equipment providers.

Headquartered in Greensboro, N.C., RFMD is an ISO 9001- and ISO 14001-certified manufacturer with worldwide engineering, design, sales and service facilities. RFMD is traded on the NASDAQ Global Select Market under the symbol RFMD.

eDOORWAYS Corporation engages in the creation of a lifestyle information / entertainment platform for the visually-oriented web surfing community. eDOORWAYS portal is a Web-based personal lifestyle information enhancement and problem solving gateway, lifestyle information source, and online business-to-consumer marketplace.
Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(tm) device. The Company's flagship product, oral insulin (Generex Oral-lyn(tm)), which is available for sale in Ecuador for the treatment of subjects with Type-1 and Type-2 diabetes and which was approved for sale in India in October 2007, is in Phase III clinical trials at several sites around the world.

GeoVax Labs, Inc. is a biotechnology company, established to develop, manufacture, license and commercialize human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents. GeoVax's AIDS vaccine technology is the subject of 20 issued or filed patent applications. GeoVax AIDS vaccines are designed for use in uninfected people to prevent Acquired Immunodeficiency Disease (AIDS), caused by the virus known as HIV-1, should the person ever become infected. GeoVax AIDS vaccines also may be effective as therapeutics (treatment of people already infected with the HIV-1 virus). Studies evaluating these vaccines in HIV/AIDS infected individuals are in the planning stage.

GeoVax's core AIDS vaccine technologies were developed through a collaboration of colleagues at Emory University's Vaccine Center, the National Institutes of Health (NIH), The Centers for Disease Control and Prevention (CDC) and the GeoVax team.

GeoVax AIDS vaccines have moved forward in human clinical trials conducted by the HIV Vaccine Trials Network (HVTN) based in Seattle, Washington. The HVTN, funded through a cooperative agreement with the National Institutes of Health (NIH), is the largest worldwide clinical trials program dedicated to the development and testing of AIDS vaccines. Preclinical work enabling evaluation of GeoVax DNA and MVA vaccines was funded and supported by NIAID, which provided additional support to GeoVax AIDS vaccine development program with a $15 million IPCAVD grant awarded in late 2007.

The Company Overview can be viewed here (.pdf)

NutriPure Beverages, Inc. is focused on growth and diversification in the multi-billion dollar healthy food / healthy water industries. NutriPure's wholly owned subsidiary XND Technologies, Inc. is bringing to market a complete line of nutrient-enhanced bottled water products under the NU2O label. Nu2O products will include a vitamin enhanced water for general health, a diet formulation for weight watchers, an immune booster, an energy and fitness drink, and additional formulations to be announced later.

Nu2O products will be the first and only premium nutrient-enhanced bottled water products to be produced using a revolutionary cold-filling process that enables the adding of organic nutrients while retaining the appearance and taste of pure water. This concept is unique because no other producer adds organic nutrients without also adding masking flavors, colors or sweeteners. NU2O products will contain no calories, no carbohydrates, no colors and no flavors other than pure water. NutriPure?s patented cold-fill process gives it several marketing advantages over its competitors: (1) This process costs 30% less than the standard hot-fill process, which translates directly to greater bottom line profits; (2) Cold-filling enhances the bioavailability of the ingredients, prevents biodegradation, and allows beverages to be bottled at neutral pH, thereby creating a more healthful product without altering the taste of the water, and (3) This process allows NutriPure to use the claims "natural", "organic", and "no preservatives" on its packaging and marketing materials. Consumer testing indicates that public awareness sees Nu2O in a special category of its own, somewhere between SmartWater and VitaminWater.

The company plans to initially launch three formulations under the Nu2O label, with three additional formulations scheduled to be introduced after the second quarter of operations. Distribution is scheduled to begin in the Southwest U.S during the first half of 2009 and to expand nationwide and internationally over the following six to eight months, contingent upon finalization of funding and staffing requirements.

MIT is a California-based public company that has developed and patented a rapid microbial ID system that can revolutionize the pathogenic ID process and annually save thousands of lives and tens of millions of dollars. The System IDs bacteria in minutes, not days, and at a significant per test cost savings when compared to any conventional method. Revenues for all rapid testing methods exceed $5 billion annually -- with food safety accounting for over $3 billion -- having expanded at a rate of 9.2 percent each year since 1998. Current growth projections are at 30 percent annually with test demands driven by major health, safety and homeland security issues.

The System is laser and optically based and uses the proven principles of light scattering in conjunction with proprietary PC-based software algorithms to ID microbes and create a proprietary database. MIT, through independent testing, has proven the ability with high accuracy to ID the most dangerous and pervasive pathogens; E. coli, Listeria, Salmonella, and Staphylococcus aureus (a.k.a. Staph) and twenty (20) other species of bacterium.

The MIT 1000 System has numerous ID applications including food quality control, clinical diagnostics, pharmaceutical quality assurance, semiconductor processing control and water quality monitoring. MIT has chosen to focus initial efforts on food quality control as recent events have created an urgent demand for quicker and cheaper testing -- demands that will promote a high-value return on any investment in MIT's technology.

Today's Picks
  • EDWY
  • UNDT
  • EWRC
  • MMTC
  • SPNG
  • ERHE
Performances
  • APDN +43%
  • CGEN +82%
  • ERHE +100%
  • GNBT +99%
  • LFBG +426%
  • NPWS +1625%
  • SPNG +726%